İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
Becton Dickinson and Company's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $48.2B | |
|---|---|---|
| Revenue (ttm) | 22.5B | |
| Net income (ttm) | 942M | |
| EPS (ttm) | $3.33 | |
| Shares out | 272.4M | |
| P/E (trailing) | 58.5x | |
| P/E (forward) | 13.7x | |
| Dividend | $4.20 (2.16%) | |
| Volume | 1,351,015 | |
| Beta | 0.28 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2026-09-30 | Trend |
| Revenue | $18.87B | $19.37B | $20.18B | $21.84B | — | +5.0% |
| Gross profit | $8.48B | $8.17B | $9.13B | $9.92B | — | +5.4% |
| Operating income | $2.28B | $2.11B | $2.40B | $2.58B | — | +4.2% |
| Net income | $1.78B | $1.48B | $1.71B | $1.68B | — | -1.9% |
| EPS (diluted) | $4.62 | $3.88 | $4.61 | $4.58 | $9.04 | +18.3% |
| EBITDA | $4.41B | $4.40B | $4.82B | $4.96B | — | +4.0% |
| R&D | $1.26B | $1.24B | $1.19B | $1.27B | — | +0.2% |
| SG&A | $4.71B | $4.72B | $4.86B | $5.28B | — | +3.9% |
Recent company headlines from major financial publishers.
The Base scenario envisions steady hospital procedure replenishment supporting core Medical and Interventional consumable franchises. Operational execution through productivity programs counterbalances selective group purchasing pricing concessions, while international markets compound at moderate single-digit rates. With the shares trading at $176.80 against our Fair value of $194.59, this outcome carries a target of $194.59 at an assigned probability of 55.0%, implying an expected return of 10.1%. Disconfirmation would emerge if core consumable volume growth turns negative or if operating margins slip below targeted levels within the next fiscal year.
The Bull scenario reflects sustained market share capture from competitor supply disruptions, accelerating Medical segment volume growth alongside expanding international adoption. Manufacturing automation and operating leverage widen operating margins toward peer benchmark levels, driving accelerated free cash flow that substantially expedites debt retirement. This upside path yields a target of $323.86 with an assigned probability of 20.0%, representing a return of 83.2% toward Potential value of $323.86. Disconfirmation would occur if competitor capacity quickly restores customer volume share or if hospital capital spending slows within the next two fiscal years.
| Ke ↓ / g → | 1.7% | 2.0% | 2.2% | 2.5% | 2.7% |
|---|---|---|---|---|---|
| 6.2% | $210 | $215 | $221 | $229 | $237 |
| 6.7% | $198 | $202 | $206 | $212 | $218 |
| 7.2% | $188 | $191 | $195 | $199 | $203 |
| 7.7% | $179 | $182 | $185 | $188 | $192 |
| 8.2% | $172 | $174 | $177 | $179 | $182 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
